Trade secrets: protecting creation and innovation in Europe

29 January 2016

European companies are renowned for their innovation but this is put at risk by industrial espionage. Parliament and the Council have provisionally agreed new rules to better protect them.

“The text voted in the Legal Affairs Committee today will make it possible to protect companies’ professional knowhow and confidential commercial information, whilst safeguarding the fundamental freedoms of expression information and of the press,“ said rapporteur Constance Le Grip (EPP, France).

The deal was endorsed by the legal affairs committee on January 28, and it will now be up to all MEPs to vote on it.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK